Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | DHODH | Q02127 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9960753 | 0.74 | KDM4E (0.34) | ALDH1A1MAPT | |
| SCHEMBL5778824 | 0.73 | MEN1 (0.48) | ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL14801053 | 0.73 | NPC1 (0.43) | GSK3BHDAC1HDAC6ALDH1A1MAPT | |
| SCHEMBL16144904 | 0.69 | RAB9A (0.37) | ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL9960479 | 0.68 | RBP4 (0.40) | ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL9961029 | 0.68 | MEN1 (0.36) | ALDH1A1MAPTSMN1; SMN2DHODH | |
| SCHEMBL15555370 | 0.68 | HDAC4 (0.36) | HDAC3HDAC1HDAC6ALDH1A1MAPT | |
| SCHEMBL9960810 | 0.68 | NR4A1 (0.41) | ALDH1A1MAPT | |
| SCHEMBL28806317 | 0.68 | ALDH1A1 (0.37) | HDAC2HDAC6ALDH1A1 | |
| SCHEMBL2457029 | 0.68 | ALDH1A1 (0.43) | ALDH1A1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655323-B1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LTD (IE) | 2017-12-20 | — | — | EP | claimed |
| US-20170217910-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LIMITED (IE) | 2017-08-03 | — | — | US | claimed |
| US-20150291551-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LIMITED (IE) | 2015-10-15 | — | — | US | claimed |
| US-9102687-B2 | Ingenol-3-acylates III and ingenol-3-carbamates | LEO LABORATORIES LIMITED (IE) | 2015-08-11 | — | — | US | claimed |
| US-20140303150-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LIMITED (IE) | 2014-10-09 | — | — | US | claimed |
| EP-2655323-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LIMITED (IE) | 2013-10-30 | — | — | EP | claimed |
| WO-2012083953-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO PHARMA A/S (DK) | 2012-06-28 | — | — | WO | claimed |
| EP-2655323-B1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LTD (IE) | 2017-12-20 | — | — | EP | disclosed |
| US-20170217910-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LIMITED (IE) | 2017-08-03 | — | — | US | disclosed |
| US-9708286-B2 | Ingenol-3-acylates III and ingenol-3-carbamates | LEO LABORATORIES LIMITED (IE) | 2017-07-18 | — | — | US | disclosed |
| US-20150291551-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LIMITED (IE) | 2015-10-15 | — | — | US | disclosed |
| US-9102687-B2 | Ingenol-3-acylates III and ingenol-3-carbamates | LEO LABORATORIES LIMITED (IE) | 2015-08-11 | — | — | US | disclosed |
| US-20150133543-A1 | TOPICAL GEL COMPOSITION COMPRISING AN INGENOL DERIVATIVE AND A SOLVENT MIXTURE | LEO LABORATORIES LIMITED (IE) | 2015-05-14 | — | — | US | disclosed |
| US-20140303150-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LIMITED (IE) | 2014-10-09 | — | — | US | disclosed |
| EP-2655323-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LIMITED (IE) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012083953-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO PHARMA A/S (DK) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217910-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | RXRB, RXRA, RXRG | GSK3B 2422/4885HDAC3 21/4885HDAC1 55/4885 |
| US-20150291551-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | RXRB, RXRA, RXRG | GSK3B 2422/4885HDAC3 21/4885HDAC1 55/4885 |
| US-20140303150-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | RXRB, RXRA, RXRG | GSK3B 2422/4885HDAC3 21/4885HDAC1 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.